![]() |
|
![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Onar®Ls - Legionella species DiagnosisKIT FOR IN VITRO DIAGNOSIS OF LEGIONELLA SPECIES
Onar®Ls system is an in vitro test for the qualitative and quantitative diagnosis of Legionella species (Ls) in clinical samples. The test is based on the polymerase chain reaction, and thus providing highly sensitive and approx. 100% specific rapid diagnosis. Onar® is CE-marked and approved for in vitro clinical diagnostics. The test system has undergone extensive internal validation, as well as external clinical evaluations. Onar®Ls is available as a conventional PCR assay with result evaluation by agarose gel, as well as a quantitative PCR probe system for use on most real-time instruments (Onar®Ls Type 1 & Type 2).
Ordering
Instrument Compatibility
+ = recommended kit version
Benefits
Test PrincipleWe deploy Onar®Ls
for the qualitative conventional PCR and Onar®Ls
Type 1 & Type 2 for the quantitative qPCR. Onar®Ls The Onar®Ls test
system is an in vitro test for the qualitative diagnosis of legionella
in clinical samples. The test is based on the polymerase chain reaction
and allows rapid diagnosis of legionella infections. The supplied primerset
is specific for a segment of the 16S rRNA region of the legionella genome.
The amplified PCR product is approx. 244 bp long and can be rendered visible
directly in the agarose gel. The internal control amplicon is 150 bp in
size. Onar®Ls Type 1 & Type 2 The Onar®Ls test systems are in vitro test for the quantitative diagnosis of legionella in clinical samples. The supplied primerset and probe are specific for a segment of the 16S rRNA region of the legionella genome. The specific target probe emits fluorescent light at 520 nm. By using the supplied internal control, false-negative results, e.g. due to inhibition of the reaction by the sample matrix, can be excluded individually for each sample. The internal control is detected by another probe emitting fluorescent light at 600 nm. Detailed clinical studies confirm the high specificity and sensitivity of Onar®Ls Type 1 & Type 2 permitting early identification of clinically significant legionella infections. The selected template is highly preserved within the Legionella species. Cross activity with pharyngeal commensals does not occur. The detection limit fewer than 10 genome equivalents per 5 µl sample volume. BackgroundLegionella spp. ubiquitously colonizes surface water and wet
soil, and are the cause of the Legionnaires`disease. Transmission is aerogenic.
Typical symptoms are high fever, cough, thorax ache, diarrhea, discomposure,
sometimes with heavy progression. The incubation period of Legionnaires'
disease is from two to ten days. If the patient is treated with appropriate
antibiotics near the onset of pneumonia, the outcome is excellent, especially
if the patient has no underlying illness that compromises his/her immune
system. For patients whose immune systems are compromised, including transplant
recipients, delay of appropriate therapy can result in prolonged hospitalization,
complications, and death. The fatality rate of Legionnaires' disease is
up to 30%. For those patients who are discharged from the hospital, many
will experience fatigue, loss of energy, and difficulty concentrating
for several months after discharge from the hospital. Kit Components
We highly recommend our reliable hot-start MB Taq DNA Polymerase for
extreme sensitive PCR detection of legionella (Cat. No. 53-0200). Onar® kit components are lyophilized and at +2 bis +8 °C maintainable for at least 12 months. Primer and nucleotides are aliquoted (á 25 tests) to guarantee consistent quality. After rehydratisation the reagents must be stored at -18 °C.
|
![]() Download
Certificate of AnalysisYou will find Your CoA of Your specific lot ins the menu below. [Download available as PDF-file]. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| top |
| Update: 03.02.2012 // Contact // International Distributors // Terms and Conditions // Site Map // © 2012 Minerva Biolabs GmbH | |